FierceBiotechOriginal article
{"a":[{"_":"GSK partner Hansoh reports another phase 3 win for priority ADC ","$":{"href":"/biotech/gsk-partner-hansoh-reports-another-phase-3-win-priority-adc","hreflang":"en"}}]}
Phase 3positiveB7-H3-directed antibody-drug conjugatePositive
AI Analysis
Summary
Hansoh Pharmaceutical's GSK-partnered B7-H3-directed antibody-drug conjugate achieved positive Phase 3 results in China, representing another clinical win for this priority asset.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Phase 3 trial met primary endpoints in China
Importance:7/10
Sentiment:
0.80
ADConcologyPhase 3ChinaGSK partnership
Read the original article
Published by FierceBiotech on July 28, 2026 7:24 AM